CTOs on the Move


 
XOMA is a late-stage biotechnology company with a diverse portfolio of innovative therapeutic antibodies. The Company has built an expertise in allosteric modulation and has applied that expertise to expand the therapeutic potential of monoclonal antibodies.  The first compound from XOMA’s allosteric modulating antibody program is gevokizumab, an IL-1 beta modulating antibody.  XOMA has partnered with SERVIER, a global pharmaceutical company based in France, to develop and commercialize gevokizumab for the global market, and the companies are conducting a global Phase 3 program in people with Behçet’s disease uveitis and non-infectious uveitis. Each company also has a proof-of-concept (POC) clinical program ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.xoma.com
  • 2910 7th St Ste 100
    Berkeley, CA USA 94710
  • Phone: 510.204.7270

Executives

Name Title Contact Details

Funding

XOMA raised $35M on 11/04/2021

Similar Companies

Mérieux NutriSciences

Mérieux NutriSciences is a service company headquartered in Chicago.

CELLEX BIOSCIENCES

CELLEX BIOSCIENCES is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Agenta Biotechnologies

Agenta Biotechnologies is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CoDa Therapeutics

CoDa Therapeutics is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Evolve Biosystems

Evolve BioSystems is a spin-out from the Foods For Health Institute (FFHI) at the University of California, Davis. The company builds on more than a decade of research into the infant gut microbiome and its unique interaction with breast milk components, established by the founding scientists including Bruce German, David Mills, Carlito Lebrilla, Daniela Barile and Samara Freeman. Their fundamental research and translational clinical trials have been enabled by more than $15 million in federal and private grants since 2004. Under the leadership of CEO Dr. David Kyle, Evolve completed a $1 million seed funding round in mid-2014, a $9 million Series A round in August 2015 and most recently a $20 million Series B capital raise in 2017. Evolve has now successfully completed a milestone proof-of-concept study to demonstrate the efficacy of its initial proprietary offering, with a series of upcoming trials scheduled across both human and animal health applications. With a strong portfolio of intellectual property developed at UC Davis, a world-class management team plus blue-chip investors, and an unwavering dedication to allowing science to direct our product development, Evolve continues to expand it`s pipeline of next generation microbiome-based solutions to establish, restore, and maintain a healthy gut microbiome.